Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moxifloxacin.

J A Balfour1, L R Wiseman

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|April 8, 1999
PubMed
Summary
This summary is machine-generated.

Moxifloxacin, a new fluoroquinolone antibiotic, shows high effectiveness against common respiratory infections like pneumonia and bronchitis. It offers broad-spectrum antibacterial activity with a favorable safety profile compared to other fluoroquinolones.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Topical eflornithine.

American journal of clinical dermatology·2001
Same author

Telithromycin.

Drugs·2001
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Microbiology

Background:

  • Moxifloxacin is a novel fluoroquinolone antibiotic.
  • It exhibits broad-spectrum activity against Gram-negative and Gram-positive bacteria.
  • It demonstrates enhanced activity against Gram-positive species and anaerobes compared to ciprofloxacin.

Purpose of the Study:

  • To evaluate the efficacy and safety of moxifloxacin in treating respiratory tract infections.
  • To compare moxifloxacin's effectiveness with existing antibiotics.
  • To assess its pharmacokinetic profile and drug interactions.

Main Methods:

  • Clinical trials were conducted in patients with community-acquired pneumococcal pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), and acute sinusitis.

Related Experiment Videos

  • Moxifloxacin 400 mg once daily was administered.
  • Efficacy was assessed by bacteriological and clinical success rates.
  • Comparisons were made with amoxicillin, clarithromycin, and cefuroxime axetil.

    • Main Results:

    • Moxifloxacin achieved high success rates (approximately 90% or higher) in CAP, AECB, and sinusitis.
    • It demonstrated comparable efficacy to amoxicillin and clarithromycin in CAP and AECB.
    • In sinusitis, a 7-day moxifloxacin course was as effective as a 10-day cefuroxime axetil course.
    • Moxifloxacin showed a low propensity for phototoxicity and CNS effects.
    • The most frequent adverse events were gastrointestinal disturbances.

    Conclusions:

    • Moxifloxacin is an effective antibiotic for treating common respiratory tract infections.
    • It offers a favorable safety profile with fewer adverse effects compared to some other fluoroquinolones.
    • Its efficacy is comparable to standard treatments, making it a valuable therapeutic option.